Skip to main content
OncoPrescribe
  • HOME
  • WHY US
  • ABOUT
  • SIGN IN
  • SIGN UP

Top Ad

hem-onc-updates

Advertisement

WELIREG® (Belzutifan)

August 28, 2021August 28, 2021 RR FDA Approvals
General Medical Oncology & Hematology

The FDA on August 13, 2021 approved WELIREG®, a Hypoxia-Inducible Factor inhibitor for adult patients with Von Hippel-Lindau (VHL) disease who require therapy for associated Renal Cell Carcinoma (RCC), Central Nervous System (CNS) Hemangioblastomas, or Pancreatic NeuroEndocrine Tumors (pNET), not requiring immediate surgery. WELIREG® is a product of Merck & Co.

Post navigation

LENVIMA® (Lenvatinib) plus KEYTRUDA® (Pembrolizumab)
JEMPERLI® (Dostarlimab-gxly)

Bottom Ad

hem-onc-updates

Advertisement

Subscribe

Subscribe

Ad 1

OncoPrescribe-Ad

Advertisement

Ad 2

OncoPrescribe-CDC

Advertisement

Ad 3

OncoPrescribe-Ad

Advertisement

Ad 4

OncoPrescribe

Advertisement

  • PRIVACY
  • TERMS
  • DISCLAIMER
  • CONTACT
OncoPrescribe, LLC. All Rights Reserved